VEGF Trap continues to impress

Article

VEGF Trap (Regeneron) maintains a significant improvement in the visual acuity of neovascular age-related macular degeneration (wet AMD) patients up to 32 weeks, according to a study presented at this year's Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).

VEGF Trap (Regeneron) maintains a significant improvement in the visual acuity of neovascular age-related macular degeneration (wet AMD) patients up to 32 weeks, according to a study presented at this year's Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Quan Dong Nguyen, MD, MSc, of the Johns Hopkins University School of Medicine in Baltimore, US, and colleagues conducted a double-masked, prospective, randomized, multicentre, Phase II trial of five groups of a cumulative 157 patients, who each received VEGF Trap in one eye.

The first group of patients received 0.5 mg of VEGF Trap monthly for 12 weeks; Group 2 received 2.0 mg of VEGF Trap monthly for 12 weeks; Group 3 received 0.5 mg at baseline and week 12; Group 4 received 2.0 mg at baseline and week 12, and Group 5 received 4.0 mg at baseline and week 12. Follow-up PRN treatment was administered at the same dose as the patient had received in the initial 12 weeks.

Across all groups, an average of one extra injection was required throughout the follow-up period. VEGF Trap was well tolerated; no drug-related adverse serious events were noted.

Groups 1 and 2 demonstrated mean VA improvements of 8.0 and 10.1 letters, respectively. VA improvements in Groups 3, 4 and 5 were less robust, although the mean VA improvement for all groups at week 32 was 6.6 letters. These results indicate that a fixed monthly dosing is a more effective method of treating wet AMD with VEGF Trap. The full 52 week Phase II study is ongoing.

A separate study published in the March 2008 issue of the British Journal of Ophthalmology also demonstrated that VEGF Trap administered intravitreally continues to bind VEGF for 10–12 weeks following injection.

Michael W. Stewart, MD of the Mayo Clinic College of Medicine, Jacksonville, US and colleagues compared VEGF Trap with Lucentis (ranibizumab; Novartis) against VEGF. Seventy-nine days following a 1.15 mg injection of VEGF Trap, intravitreal VEGF binding was comparable to that achieved 30 days after an injection of Lucentis.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.